Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia (original) (raw)
Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review
Miquel Bioque, Alexandre G González-Rodríguez, Rafael Penadés
Patient preference and adherence, 2015
View PDFchevron_right
A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia
Panna Sanga
International Journal of Neuropsychopharmacology, 2021
View PDFchevron_right
Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review
Clemente Garcia-rizo, Rafael Penadés, Alexandre G González-Rodríguez
Patient Preference and Adherence, 2015
View PDFchevron_right
Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
Helio Elkis
Neuropsychiatric Disease and Treatment
View PDFchevron_right
Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response …
Paulien Ravenstijn
International clinical …, 2010
View PDFchevron_right
Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia
Cherubin, Pierre [JACFR], Andreas Schreiner
Schizophrenia Research, 2015
View PDFchevron_right
Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
Adam Savitz
The International Journal of Neuropsychopharmacology, 2016
View PDFchevron_right
A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents
Ludger Hargarter, Andreas Schreiner, Yasin Bez
Clinical therapeutics, 2014
View PDFchevron_right
A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia
Pilar Lim
Neuropsychopharmacology, 2010
View PDFchevron_right
Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration
Euitae Kim
The Journal of Clinical Psychiatry, 2021
View PDFchevron_right
Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia
Nagahide Takahashi
Neuropsychiatric Disease and Treatment, 2013
View PDFchevron_right
A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
Ahmad Hatim Sulaiman
Bmc Psychiatry, 2012
View PDFchevron_right
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
Adam Savitz
Neuropsychiatric Disease and Treatment, 2019
View PDFchevron_right
Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study
Cenk Varlik
International Clinical Psychopharmacology, 2010
View PDFchevron_right
Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia
Andreas Conca
Expert Opinion on Pharmacotherapy, 2016
View PDFchevron_right
Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study
Robert Litman
The International Journal of Neuropsychopharmacology, 2009
View PDFchevron_right
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia
Lian Mao
CNS spectrums, 2016
View PDFchevron_right
A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia
Pilar Lim
Journal of Psychopharmacology, 2011
View PDFchevron_right
Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study
Adam Savitz
The Journal of Clinical Pharmacology, 2015
View PDFchevron_right
Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical Setting
Ahmad Hatim Sulaiman
Clinical Psychopharmacology and Neuroscience
View PDFchevron_right
Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
Peter Weiden
Patient Preference and Adherence, 2012
View PDFchevron_right
Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
Boran Uglešić
Neuropsychiatric Disease and Treatment
View PDFchevron_right
Effectiveness of Paliperidone Palmitate vs. Haloperidol Decanoate for Maintenance Treatment of Schizophrenia: A Randomized Clinical Trial NIH Public Access Author Manuscript
Pablo Menendez
View PDFchevron_right
Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics
Ludger Hargarter, Sofia Keim, Paul Bergmans
Progress in neuro-psychopharmacology & biological psychiatry, 2015
View PDFchevron_right